Advances in Immunotherapy for Glioblastoma Multiforme

Table 3

Representative clinical trials of immune checkpoint blockade in glioma.

Registration number	New/recurrent/metastatic	Mechanism	Therapy	Number of patients	Phase
NCT02017717	Recurrent	Anti-PD1, anti-CTLA4	Nivolumab, ipilimumab, bevacizumab		Phase III
NCT02336165	New + recurrent	Anti-PDL1	MEDI4736, Bevacizumab,		Phase II
NCT02311920	New + recurrent	Anti-PD1, anti-CTLA4	TMZ, nivolumab, ipilimumab		Phase I
NCT02337491	Recurrent	Anti-PD1	Pembrolizumab, bevacizumab		Phase II
NCT01952769	Recurrent	Anti-PD1	Pidilizumab		Phase I/II